Clinical trials: Approved Alternative Therapy
Cutaneous or Subcutaneous Tumors Where There is no Comparable or Satisfactory, Approved Alternative Therapy
Expanded Access Protocol for PV-10 for Cutaneous or Subcutaneous Tumors
This compassionate use protocol provides expanded access for investigational use of PV-10 in cancer patients who are not eligible for an existing PV-10 clinical trial, for whom there is no comparable or satisfactory approved…
- Trial name
- NCT01260779
- Testing
- PV-10 (10% rose bengal disodium)
- Where
- 6 sites in United States, Australia
- Sponsor
- Provectus Biopharmaceuticals, Inc.
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Multiple Sclerosis
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares.
- Trial name
- NCT00273364
- Testing
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Northwestern University
Advanced Solid Tumors
A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors
The aim of this study is to determine the safety, tolerability and anti-tumoral activity of autologous T cells transduced with a T cell receptor specific for MAGE-A1 in eligible patients with advanced solid tumors.
- Trial name
- IMAG1NE (NCT05430555)
- Testing
- Autologous CD8+ T-cells, transduced with MAGE-A1 directed TCR
- Where
- 14 sites in Belgium, Germany and 3 more
- Volunteers
- 23 people
- Sponsor
- T-knife GmbH